Oncology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region and Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 220.67 Billion

CAGR (2024-2029)

13.21%

Fastest Growing Segment

Targeted Drugs

Largest Market

North America

Market Size (2029)

USD 462.66 Billion


Market Overview

Global Oncology Drugs Market was valued at USD 220.67 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 13.21% through 2029. A multitude of diseases, including cancer, arise from abnormal cell growth in various organs or tissues. The increasing mortality rate from cancer, coupled with population growth, places a significant physical and financial burden on individuals, families, and the global healthcare system. Surgery, oncology drugs, radiation therapy, immunotherapy, and a range of other treatments are employed in the management of cancer, depending on the type and stage of the disease. Physicians may prescribe specific medications aimed at impeding the metabolism of cancer cells or damaging their DNA. In the global effort to combat cancer, diverse drug classes are utilized for various types of cancer. Cancer medications are utilized to treat, eliminate, manage, and prevent the spread of cancer cells to other organs and tissues. They are combined with oncology drugs, immunotherapy, radiation therapy, and other treatment options. They can alleviate symptoms such as pain, rashes, and nausea. The specific type or class of medication required for treatment depends on factors such as the type and stage of cancer, as well as the potential side effects when combined with other drugs. Several malignant growth drugs have received FDA approval and are widely used by oncologists. The global demand for cancer medications is increasing in response to the growing number of cancer patients.

Key Market Drivers

Extensive Research and Development into New Cancer Drugs and Treatments

Extensive research and development (R&D) efforts into new cancer drugs and treatments are poised to drive a significant increase in the demand for oncology drugs. The relentless pursuit of more effective therapies and a deeper understanding of cancer biology has resulted in a robust pipeline of promising oncological innovations, which are set to transform the landscape of cancer care in the future.  As researchers unravel the genetic and molecular intricacies of various cancer types, they identify specific vulnerabilities that can be exploited for treatment. Precision medicine, which tailors’ therapies based on the individual patient's genetic profile, is gaining prominence, driving the demand for targeted therapies and companion diagnostics. These therapies offer higher efficacy and reduced side effects compared to traditional treatments, making them highly sought after.

Immunotherapy has emerged as a groundbreaking approach in oncology. Checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines are among the innovative immunotherapies that have demonstrated remarkable success in treating some of the most challenging malignancies. The ongoing research and development in this field, including efforts to expand the applicability of immunotherapies to a broader range of cancers, are expected to significantly boost demand for these treatments. The extensive research and development into new cancer drugs and treatments are propelling the oncology drug market into an era of unprecedented growth. With a focus on precision medicine, immunotherapy, and the expanding understanding of cancer biology, the demand for oncology drugs is set to surge as patients and healthcare providers seek more effective and tailored therapies to combat this complex and multifaceted disease.

Increasing Prevalence of Cancer

The rising prevalence of cancer is estimated to significantly enhance the growth rate of the oncology drugs drug market. According to the World Health Organization (WHO), cancer stands as the leading cause of mortality worldwide, responsible for approximately 10 million deaths in 2020 alone. This devastating disease accounts for nearly one in every six deaths globally, highlighting the urgent need for effective treatments. Shockingly, it is not just adults who are affected by cancer. Around 400,000 children are diagnosed with this debilitating illness every year, emphasizing the alarming impact on younger populations.

The burden of cancer on society is further underscored by the fact that cervical cancer, a form of cancer that affects the cervix, holds the unfortunate distinction of being the most frequent cancer in 23 countries across the globe. In the battle against cancer, oncology drugs has emerged as the most common treatment modality. It often serves as a vital component, working in conjunction with other cancer treatments to combat the disease. Specifically, neo-adjuvant oncology drugs, administered before surgery and radiation therapy, aims to shrink tumor cells, while adjuvant oncology drugs, given after surgery or radiation therapy, works towards further reducing the tumor cell size. However, the fight against cancer is not without hope. Continuous advancements in oncology drugs and its integration with other treatment modalities offer promise and progress. Researchers and healthcare professionals are tirelessly working to improve the efficacy and minimize the side effects of oncology drugs, bringing us closer to a world where cancer can be treated effectively, and lives can be saved.

Increasing Investment for Healthcare Infrastructure  

Another significant factor impacting the growth rate of the oncology drugs drug market is the increasing healthcare expenditure, which plays a vital role in enhancing the infrastructure required for effective treatment. With the continuous rise in healthcare spending, hospitals and healthcare facilities can invest in advanced technologies, state-of-the-art equipment, and highly skilled medical professionals. These investments contribute to the overall development of the healthcare infrastructure.

Various government organizations are actively working towards enhancing the healthcare infrastructure by allocating additional funding. This increased investment not only supports the expansion of healthcare facilities but also promotes research and development in the field of oncology drugs. Consequently, these market dynamics pave the way for innovation, improved patient care, and better treatment outcomes. In summary, the combined efforts of rising healthcare expenditure and government initiatives focused on improving the healthcare infrastructure are driving the growth of the oncology drugs drug market. These developments hold the promise of providing advanced treatment options and ensuring better healthcare services for patients in need.

Rise In Demand for Advanced Cancer Drugs

The rise in demand for advanced cancer drugs represents a compelling force that is expected to significantly boost the demand for oncology drugs in the healthcare industry. This surge in demand is fueled by several key factors, each contributing to the growing need for cutting-edge therapies in the fight against cancer. The evolving landscape of cancer care places a strong emphasis on precision medicine. As our understanding of cancer genetics and molecular pathways deepens, the demand for targeted therapies tailored to the genetic makeup of individual patients is on the rise. These advanced cancer drugs are designed to specifically target cancer cells while sparing healthy tissue, offering improved efficacy and reduced side effects compared to traditional treatments. The rise in demand for advanced cancer drugs reflects the evolving landscape of cancer care, emphasizing precision medicine, immunotherapy, and the pressing need for innovative treatments. This demand surge is expected to propel the oncology drug market forward, offering new hope to cancer patients and reshaping the future of cancer treatment.


Download Free Sample Report

Key Market Challenges

Adverse Effect of Anti-Cancer Drugs

Drugs used in oncology drugs are designed to target and eliminate rapidly dividing cells, a hallmark of cancer cells. However, their mechanism of action often leads to unintended consequences, as they cannot differentiate between healthy cells and cancerous cells. One of the most common adverse effects of anti-cancer drugs is the damage they cause to blood-forming cells in the bone marrow, potentially resulting in anemia and compromised immune function.

The impact of these medications extends beyond the hematological system. The hair follicles can become damaged, leading to hair loss, which can have a profound psychological impact on patients. Nausea, constipation, and fertility problems are additional serious side effects that can significantly affect the quality of life for individuals undergoing oncology drugs. In the case of head and neck cancer treatment, specific drugs can cause a range of side effects. These include rashes, itching, weight loss, mouth sores, and issues with the nerves and muscles, such as numbness, pain, and tingling sensations. These symptoms can further exacerbate the physical and emotional burden experienced by patients. Given these severe adverse effects, the development and progress of the global market for cancer medications face significant challenges. Efforts to improve treatment outcomes for cancer patients should not only focus on the efficacy of the drugs but also on minimizing the adverse effects that can impact their overall well-being.

High Cost Associated with the Oncology Drugs

The high cost associated with oncology drugs is expected to greatly hinder the growth rate of the market. The scarcity of skilled professionals and inadequate healthcare infrastructure in developing economies will pose significant challenges to the oncology drugs drug market. In addition to these challenges, the side effects of oncology drugs, such as heart problems, decreased red blood cell count, fatigue, weight loss, hair loss, diarrhea, decreased lung, kidney, and liver quality, reduced bone density, and lack of awareness among people, will act as restraints and further impede the growth rate of the market during the forecast period. These factors collectively contribute to the complex landscape of the oncology drugs drug market and highlight the need for comprehensive strategies to address these obstacles.

Key Market Trends

Development of Innovative Technology

Oncology drugs, a crucial treatment in the battle against cancer, has greatly extended the lives of patients beyond what was previously possible. In the latest breakthrough in the field, scientists have developed a novel approach using customized nanoparticles to deliver cancer-fighting medications directly to affected areas, sparing healthy cells from harm. This cutting-edge method has demonstrated remarkable efficacy in eliminating malignant cells while preserving the integrity of surrounding healthy tissue. In order to precisely monitor the release, duration, and distribution of these medications, doctors employ advanced photon lasers that track the movement of these specially designed nanoparticles through the patient's body. Building upon these promising results, the University of California, Los Angeles, is currently conducting a clinical trial to further validate the effectiveness of this approach, particularly in the treatment of lower-stage cancer patients. With its potential to revolutionize cancer treatment, this innovative technique is poised to make a significant impact in the field of oncology drugs in the foreseeable future.

Growing Adoption and Preference for Targeted Therapy in Emerging Regions

The growing adoption and preference for targeted therapy in emerging regions represent a significant driver expected to boost the demand for oncology drugs. Targeted therapy has gained prominence in recent years due to its precision in treating cancer by specifically targeting cancer cells or their molecular pathways while minimizing damage to healthy cells.

Targeted therapy offers an effective and well-tolerated alternative to traditional chemotherapy, which often carries severe side effects. Patients in emerging regions, like anywhere else, seek therapies that improve their quality of life during treatment. Targeted drugs align with this preference by providing a more targeted and tolerable treatment experience. Advancements in diagnostic technologies, including molecular profiling and genetic testing, have become more accessible in emerging regions. These tools enable healthcare providers to identify specific genetic mutations or biomarkers driving a patient's cancer, facilitating the selection of the most appropriate targeted therapy. As diagnostic capabilities expand, the demand for corresponding targeted drugs increases. Increasing investment in healthcare infrastructure, research, and pharmaceutical markets in emerging regions contributes to greater access to advanced oncology drugs, including targeted therapies. This growing accessibility, coupled with healthcare professionals' awareness and expertise, supports the expansion of targeted therapy options in these regions.

Segmental Insights

Drug Class Insights

Based on drug class, targeted drugs emerged as the fastest growing segment in 2023. This can be attributed to the numerous advantages it offers, such as its ability to specifically target proteins involved in tumorigenesis. By focusing on specific molecular changes unique to each cancer type, targeted therapy provides a more precise and effective treatment approach. One of the key factors driving the growth of the oncology/cancer drugs market is the minimal adverse effects associated with targeted therapy. The availability of a wide range of targeted therapeutics has also contributed to the market's expansion. The continuous development and innovation in this field are expected to further drive the growth of the oncology drugs market in the coming years.

Route of Administration Insights

Based on the Route of Administration segment, the oral segment dominated the market as oral medications offer a level of convenience that intravenous (IV) or other routes of administration cannot match. Patients can take oral pills or capsules at home, eliminating the need for frequent hospital visits for infusions or injections. This convenience reduces the burden on patients and their caregivers and can lead to better treatment adherence. For many cancer patients, oral drugs can enhance their overall quality of life. They allow individuals to maintain their daily routines, continue working, and enjoy a greater sense of normalcy during treatment, as they do not require prolonged hospital stays.


Download Free Sample Report

Regional Insights

In 2023, North America emerged as the leading contributor to revenue, and this trend is expected to continue its dominance. This can be attributed to several factors, including the presence of a large patient population, a strong presence of key players in the healthcare industry, easy availability of drugs, a well-developed healthcare infrastructure, favorable reimbursement policies, a higher number of research, development, and innovation activities, and a greater adoption of advanced therapeutics.

Recent Developments

  • In May 2023, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted approval for EPKINLYTM (epcoritamab-bysp), marking it as the first and only T-cell engaging bispecific antibody authorized for treating adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL), following two or more lines of systemic therapies. EPKINLY received approval under the FDA's Accelerated Approval program based on response rate and durability of response. Continued approval for this indication may be subject to confirmation and description of clinical benefit in further trials. EPKINLY is a collaborative development effort between AbbVie and Genmab under their oncology collaboration.

Key Market Players

  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Astrazeneca Plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Abbvie Inc.
  • Johnson & Johnson

 

By Drug Class

By Route of Administration

By Distribution Channel

By Region
  • Cytotoxic Drugs
  • Targeted Drugs
  • Hormonal Drugs
  • Others
  • Oral
  • Parenteral
  • Others
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Oncology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Oncology Drugs Market, By Drug Class:

o Cytotoxic Drugs

o Targeted Drugs

o Hormonal Drugs

o Others

  • Oncology Drugs Market, By Route of Administration:

o Oral

o Parenteral

o Others

  • Oncology Drugs Market, By Distribution Channel:

o Hospital Pharmacies

o Retail Pharmacies

o Others

  • Oncology Drugs Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia-Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Drugs Market.

Available Customizations:

Global Oncology Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Oncology Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validations

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Oncology Drugs Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others)

5.2.2.    By Route of Administration (Oral, Parenteral, Others)

5.2.3.    By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

5.2.4.    By Region

5.2.5.    By Company (2023)

5.3.  Market Map

6.    North America Oncology Drugs Market Outlook

6.1.  Market Size & Forecast       

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Drug Class

6.2.2.    By Route of Administration

6.2.3.    By Distribution Channel

6.2.4.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Oncology Drugs Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.            By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.            By Drug Class

6.3.1.2.2.            By Route of Administration

6.3.1.2.3.            By Distribution Channel

6.3.2.    Canada Oncology Drugs Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.            By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.            By Drug Class

6.3.2.2.2.            By Route of Administration

6.3.2.2.3.            By Distribution Channel

6.3.3.    Mexico Oncology Drugs Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.            By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.            By Drug Class

6.3.3.2.2.            By Route of Administration

6.3.3.2.3.            By Distribution Channel

7.    Europe Oncology Drugs Market Outlook

7.1.  Market Size & Forecast       

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Drug Class

7.2.2.    By Route of Administration

7.2.3.    By Distribution Channel

7.2.4.    By Country

7.3.  Europe: Country Analysis

7.3.1.    Germany Oncology Drugs Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Drug Class

7.3.1.2.2.            By Route of Administration

7.3.1.2.3.            By Distribution Channel

7.3.2.    United Kingdom Oncology Drugs Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Drug Class

7.3.2.2.2.            By Route of Administration

7.3.2.2.3.            By Distribution Channel

7.3.3.    Italy Oncology Drugs Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecasty

7.3.3.2.1.            By Drug Class

7.3.3.2.2.            By Route of Administration

7.3.3.2.3.            By Distribution Channel

7.3.4.    France Oncology Drugs Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.            By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.            By Drug Class

7.3.4.2.2.            By Route of Administration

7.3.4.2.3.            By Distribution Channel

7.3.5.    Spain Oncology Drugs Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.            By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.            By Drug Class

7.3.5.2.2.            By Route of Administration

7.3.5.2.3.            By Distribution Channel

8.    Asia-Pacific Oncology Drugs Market Outlook

8.1.  Market Size & Forecast       

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Drug Class

8.2.2.    By Route of Administration

8.2.3.    By Distribution Channel

8.2.4.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Oncology Drugs Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Drug Class

8.3.1.2.2.            By Route of Administration

8.3.1.2.3.            By Distribution Channel

8.3.2.    India Oncology Drugs Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Drug Class

8.3.2.2.2.            By Route of Administration

8.3.2.2.3.            By Distribution Channel

8.3.3.    Japan Oncology Drugs Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Drug Class

8.3.3.2.2.            By Route of Administration

8.3.3.2.3.            By Distribution Channel

8.3.4.    South Korea Oncology Drugs Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Drug Class

8.3.4.2.2.            By Route of Administration

8.3.4.2.3.            By Distribution Channel

8.3.5.    Australia Oncology Drugs Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Drug Class

8.3.5.2.2.            By Route of Administration

8.3.5.2.3.            By Distribution Channel

9.    South America Oncology Drugs Market Outlook

9.1.  Market Size & Forecast       

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Drug Class

9.2.2.    By Route of Administration

9.2.3.    By Distribution Channel

9.2.4.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Oncology Drugs Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Drug Class

9.3.1.2.2.            By Route of Administration

9.3.1.2.3.            By Distribution Channel

9.3.2.    Argentina Oncology Drugs Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Drug Class

9.3.2.2.2.            By Route of Administration

9.3.2.2.3.            By Distribution Channel

9.3.3.    Colombia Oncology Drugs Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Drug Class

9.3.3.2.2.            By Route of Administration

9.3.3.2.3.            By Distribution Channel

10.  Middle East and Africa Oncology Drugs Market Outlook

10.1.            Market Size & Forecast         

10.1.1. By Value

10.2.            Market Share & Forecast

10.2.1. By Drug Class

10.2.2. By Route of Administration

10.2.3. By Distribution Channel

10.2.4. By Country

10.3.            MEA: Country Analysis

10.3.1. South Africa Oncology Drugs Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Drug Class

10.3.1.2.2.         By Route of Administration

10.3.1.2.3.         By Distribution Channel

10.3.2. Saudi Arabia Oncology Drugs Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Drug Class

10.3.2.2.2.         By Route of Administration

10.3.2.2.3.         By Distribution Channel

10.3.3. UAE Oncology Drugs Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Drug Class

10.3.3.2.2.         By Route of Administration

10.3.3.2.3.         By Distribution Channel

11.  Market Dynamics

11.1.            Drivers

11.2.            Challenges

12.  Market Trends & Developments

12.1.            Merger & Acquisition (If Any)

12.2.            Product Launches (If Any)

12.3.            Recent Developments

13.  Porters Five Forces Analysis

13.1.            Competition in the Industry

13.2.            Potential of New Entrants

13.3.            Power of Suppliers

13.4.            Power of Customers

13.5.            Threat of Substitute Products

14.  Competitive Landscape

14.1.            Astellas Pharma Inc.

14.1.1. Business Overview

14.1.2. Company Snapshot

14.1.3. Products & Services

14.1.4. Financials (As Reported)

14.1.5. Recent Developments

14.1.6. Key Personnel Details

14.1.7. SWOT Analysis

14.2.            Pfizer, Inc.

14.3.            Novartis AG

14.4.            Astrazeneca Plc

14.5.            Merck & Co., Inc.

14.6.            F. Hoffmann-La Roche Ltd.

14.7.            Amgen, Inc.

14.8.            Bristol-Myers Squibb Company

14.9.            Abbvie Inc.

14.10.         Johnson & Johnson

15.  Strategic Recommendations

16.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Oncology Drugs Market was estimated to be USD 220.67 Billion in 2023.

down-arrow

The targeted drugs segment is the leading contributor to the market and is projected to experience growth throughout the forecast period. The identification of molecular targets expressed by cancer cells primarily drives the rapid expansion of targeted therapy utilization. Numerous targeted therapies have been approved for cancer treatment.

down-arrow

North America holds a dominant position and is projected to grow high during the forecast period. The region's strong treatment options, increasing product approvals, and growing public awareness of early cancer detection are among the key factors driving the market's continuous expansion. This anticipated growth is expected to occur in the near future.

down-arrow

Increase in prevalence of cancer disease and rise in incidence of various cancer conditions are the major drivers for the Global Oncology Drugs Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Oncology Drugs Market to Grow with a CAGR of 13.21% through 2029

May, 2024

Extensive research and development into new cancer drugs and treatments is expected to drive the Global Oncology Drugs Market growth in the forecast period, 2025-2029.

Why Choose Us